alexa Lupus nephritis | Canada | PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

  • 15th International Conference on Nephrology & Therapeutics
    August 28-30, 2017 Philadelphia, USA
  • 16th European Nephrology Conference
    October 02-04, 2017 Barcelona, Spain
  • 16th European Nephrology Conference
    October 02-04, 2017 Barcelona, Spain
  • World Nephrology Congress
    Osaka, Japan Oct 09-11, 2017
  • 13th World Nephrology Conference
    October 18-19, 2017 Dubai,UAE
  • 16th International Conference on Nephrology
    NOVEMBER 02-03, 2017 Atlanta, USA
Read more

Recommended Journals

Relevant Topics

Lupus Nephritis

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Lupus nephritis

    Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE). Also called lupus, SLE is an autoimmune disease. With lupus, the body's immune system targets its own body tissues. Lupus nephritis happens when lupus involves the kidneys.

  • Lupus nephritis

    Childhood-onset systemic lupus erythematosus (cSLE) is a rare but severe autoimmune disease with multisystem involvement, the incidence is 0.3/100000-0.9/100000 children-per year with a prevalence of 3.3/100000-8.8/100000 children. A higher frequency of cSLE is reported in Asians, African Americans, Hispanics, and native Americans. Median age of onset of cSLE is between 11 and 12 years (rare below 5 years), and 80% of patients are female. cSLE follows a more severe disease course than adult-onset SLE, with higher morbidity and lower survival rates.

  • Lupus nephritis

    Originally SLE nephritis was treated by steroids with a poor outcome which improved markedly with the introduction of cyclophosphamide. The first controlled trial reporting the short-term efficacy of cyclophosphamide for lupus nephritis in adults was published in 1971. Initially this combination was advocated for a prolonged period, but unfortunately the improved outcome was found to be associated with long-term side effects, which resulted in a further search for a less toxic, but equally effective regime. Most of the studies have been performed in adults and to a large extent the current recommendations are borrowed heavily from adult studies. The current therapeutic strategy for SLE nephritis distinguishes two distinct phases of treatment. The first phase is INDUCTION therapy which aims to control disease activity by inducing remission of disease flare (which may be the initial presentation or represent a new flare). It is at this point that potential organ-threatening and/or life-threatening disease needs to be aggressively treated. The second phase is MAINTENANCE, wherein the target is to avoid relapses and control the disease by limiting inflammation and damage.

  • Lupus nephritis

    Genentech, Inc. (NYSE: DNA) and Biogen Idec (Nasdaq: BIIB) announced that a Phase III study of Rituxan® (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks. The primary endpoint evaluated improvements in kidney response as measured by standard laboratory tests used to assess kidney health. A preliminary analysis of the safety data did not reveal any new or unexpected safety signals in patients receiving Rituxan

Expert PPTs

Speaker PPTs

 

High Impact List of Articles

Conference Proceedings

adwords